Clinical Trials Browser

Terminated × INDUSTRY × farletuzumab × Clear all

NCT00849667 2022-12-30

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Phase 3 Terminated

1,100 enrolled 30 charts

Ovarian Neoplasms

NCT01018563 2021-12-08

An Open Label Extension Study of the Efficacy of MORAb-003

Phase 2 Terminated

3 enrolled 12 charts

Carcinoma, Ovarian Epithelial

NCT00738699 2017-03-30

FAR-122

Phase 2 Terminated

415 enrolled 11 charts

Ovarian Neoplasms